OncoMatch/Clinical Trials/NCT05367206

Neoadjuvant Chemotherapy Followed by Chemoradiation Versus Chemoradiation for Stage IIIC Cervical Cancer Patients: A Randomized Phase III Trial

Is NCT05367206 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Albumin-Bound Paclitaxel and Carboplatin for cervical cancer.

Phase 3RecruitingSun Yat-sen UniversityNCT05367206Data as of May 2026

Treatment: Albumin-Bound Paclitaxel · Carboplatin — Evaluate the efficacy and safety of neoadjuvant chemotherapy (NAC) with albumin-bound paclitaxel and carboplatin followed by chemoradiation therapy (CRT) for stage IIIC cervical cancer patients with carcinoma \>4 cm in greatest dimension and/or lymph node \>2cm in short axis.

Check if I qualify

Extracted eligibility criteria

Cancer type

Cervical Cancer

Disease stage

Required: Stage IIIC

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

No prior treatment (treatment-naive required)

Lab requirements

Blood counts

adequate organ function

Kidney function

adequate organ function

Liver function

adequate organ function

adequate organ function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify